<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814004</url>
  </required_header>
  <id_info>
    <org_study_id>XYFY2021-KL062</org_study_id>
    <nct_id>NCT04814004</nct_id>
  </id_info>
  <brief_title>Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors</brief_title>
  <official_title>Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kai Lin Xu; Jun Nian Zheng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>North Jiangsu People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Changzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Jiangsu University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huai 'an First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xuzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and feasibility of hCD19.IL15.CAR-iNKT cells in&#xD;
      treating patients with relapsed/refractory/high-risk B-cell tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD19 CAR-T has been shown to treat a variety of refractory or recurrent B-cell tumors.&#xD;
      Because most CAR-T cells are generated from the patient's own T cells and are individualized&#xD;
      products, and there are individual differences between patients, the generation of customized&#xD;
      CAR-T cells is an expensive and time-consuming process. Universal CAR- iNKT cells are an&#xD;
      ideal product for cell therapy. In this study, we prepared universal iNKT cells expressing&#xD;
      hCD19 CAR and IL-15 to treat refractory, relapsed, or high-risk B-cell tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>Baseline up to 28 days after T cell infusion</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v5.0 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRD negative overall response rate (MRD- ORR)</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of MRD negative overall response rate (MRD- ORR) at 3 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Month 6, 12, 18 and 24</time_frame>
    <description>Assessment of ORR (ORR = CR + CRi ) at Month 6, 12, 18 and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Month 6, 12, 18 and 24</time_frame>
    <description>Assessment of EFS at Month 6, 12, 18 and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Month 6, 12, 18 and 24</time_frame>
    <description>Assessment of OS at Month 6, 12, 18 and 24</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>B-cell Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>hCD19.IL15.CAR-iNKT cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCD19.IL15.CAR-iNKT</intervention_name>
    <description>Universal hCD19.IL15.CAR-iNKT cells by a single infusion intravenously will be given in escalating doses.</description>
    <arm_group_label>hCD19.IL15.CAR-iNKT cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged 5-70 years;&#xD;
&#xD;
          -  The patient's ECOG score was ≤2, and the expected survival time of &gt; was 12 weeks.&#xD;
&#xD;
          -  The patient was diagnosed with B-cell tumor by pathological and histological&#xD;
             examination and had no effective treatment options, such as recurrence after&#xD;
             chemotherapy or hematopoietic stem cell transplantation. Or the patient voluntarily&#xD;
             chooses the infusion of CAR-INKT cells as the first treatment.&#xD;
&#xD;
          -  B cell tumors include the following three types:&#xD;
&#xD;
               1. B-cell acute lymphocytic leukemia (B-ALL);&#xD;
&#xD;
               2. Inert B-cell lymphoma (CLL, FL, MZL, LPL, HCL);&#xD;
&#xD;
               3. Aggressive B-cell lymphoma (DLBCL, BL, MCL);&#xD;
&#xD;
          -  Subject:&#xD;
&#xD;
               1. Residual lesions remain after primary treatment and are not suitable for HSCT&#xD;
                  (Auto/Allo-HSCT);&#xD;
&#xD;
               2. relapse after complete response (CR1) and unsuitable for allogeneic/autologous&#xD;
                  HSCT;&#xD;
&#xD;
               3. Patients with high risk factors;&#xD;
&#xD;
               4. relapse or no remission after hematopoietic stem cell transplantation or cellular&#xD;
                  immunotherapy.&#xD;
&#xD;
          -  having measurable or evaluable lesions;&#xD;
&#xD;
          -  The main tissues and organs of the patient function well:&#xD;
&#xD;
               1. Liver function: ALT/AST &lt; 3 times the upper limit of normal (ULN);&#xD;
&#xD;
               2. Renal function: creatinine &lt; 220μmol/L;&#xD;
&#xD;
               3. Lung function: indoor oxygen saturation ≥95%;&#xD;
&#xD;
               4. Heart function: left ventricular ejection fraction (LVEF) ≥40%.&#xD;
&#xD;
          -  Patients or their legal guardians voluntarily participate and sign the informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women, or women who plan to become pregnant within six months;&#xD;
&#xD;
          -  Infectious diseases (e.g. HIV, active hepatitis B or C infection, active tuberculosis,&#xD;
             etc.);&#xD;
&#xD;
          -  GVHD;&#xD;
&#xD;
          -  Abnormal vital signs and failure to cooperate with the examination;&#xD;
&#xD;
          -  People with mental or mental illness who are unable to cooperate with treatment and&#xD;
             efficacy evaluation;&#xD;
&#xD;
          -  People with high allergic constitution or severe allergic history, especially those&#xD;
             allergic to IL-2;&#xD;
&#xD;
          -  Subjects with systemic infection or severe local infection need anti-infection&#xD;
             therapy;&#xD;
&#xD;
          -  Complicated with dysfunction of heart, lung, brain, liver, kidney and other important&#xD;
             organs;&#xD;
&#xD;
          -  Any unstable systemic disease: including but not limited to unstable angina pectoris,&#xD;
             cerebrovascular accident or transient cerebral ischemia (within 6 months before&#xD;
             screening), myocardial infarction (within 6 months before screening), congestive heart&#xD;
             failure (NYHA classification ≥III);&#xD;
&#xD;
          -  Doctors believe that there are other reasons for not being included in treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kailin Xu, Ph.d</last_name>
    <role>Study Chair</role>
    <affiliation>The Affiliated Hospital of Xuzhou Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Junnian Zheng, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Xuzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang Cao, Ph.D</last_name>
    <phone>86-516-85802007</phone>
    <email>zimu05067@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Shi, Ph.D</last_name>
    <phone>86-516-85802635</phone>
    <email>sm200@sohu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated hospital of Xuzhou medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Cao, M.D., Ph.D.</last_name>
      <phone>86-516-85802007</phone>
      <email>zimu05067@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Xuzhou Medical University</investigator_affiliation>
    <investigator_full_name>Kai Lin Xu; Jun Nian Zheng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

